Literature DB >> 17765999

[Neuromuscular and architectural alterations of the vastus lateralis muscle in elderly patients with unilateral knee osteoarthritis].

S Mairet1, O Maïsetti, E Rolland, P Portero.   

Abstract

AIM: The aim of this study was to determine the mechanisms involved in muscle weakness in elderly patients with unilateral knee osteoarthritis.
SUBJECTS: We investigated 7 patients with unilateral knee osteoarthritis.
METHOD: We measured knee position sense and isometric maximal voluntary contraction (MVC) of the knee extensors. Electromyographic (EMG) measurement of biceps femoris (BF), rectus femoris (RF), vastus lateralis (VL) and vastus medialis (VM) involved different levels of contraction (25, 50, 75 and 100% MVC). Neuromuscular efficiency of quadriceps was also calculated (MVC/EMG). Ultrasonography was used to investigate the VL architectural parameters at the median part of the VL for different levels of contraction (25, 50, and 75% MVC). All tests were performed on the osteoarthritic and healthy knees.
RESULTS: The quadriceps MVC of the affected knee was reduced by 30%. The VL thickness of the affected knee was 10% smaller than that of the unaffected knee. VL activity seen on EMG did not differ between knees, but RF, VM and BF activity was greater in the unaffected than affected knee. Neuromuscular efficiency was higher (26%) in the unaffected knee. Knee position sense was reduced by 33% in the affected knee.
CONCLUSION: Quadriceps weakness associated with knee osteoarthritis seems to be related to changes in muscle rather than pennation angle and changes in fascicule length.

Entities:  

Mesh:

Year:  2007        PMID: 17765999     DOI: 10.1016/j.annrmp.2007.07.003

Source DB:  PubMed          Journal:  Ann Readapt Med Phys        ISSN: 0168-6054


  1 in total

1.  The longitudinal relationship between thigh muscle mass and the development of knee osteoarthritis.

Authors:  N A Segal; C Findlay; K Wang; J C Torner; M C Nevitt
Journal:  Osteoarthritis Cartilage       Date:  2012-09-03       Impact factor: 6.576

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.